544 reports of this reaction
1.9% of all CEFEPIME HYDROCHLORIDE reports
#9 most reported adverse reaction
ENCEPHALOPATHY is the #9 most commonly reported adverse reaction for CEFEPIME HYDROCHLORIDE, manufactured by Sagent Pharmaceuticals. There are 544 FDA adverse event reports linking CEFEPIME HYDROCHLORIDE to ENCEPHALOPATHY. This represents approximately 1.9% of all 28,358 adverse event reports for this drug.
Patients taking CEFEPIME HYDROCHLORIDE who experience encephalopathy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ENCEPHALOPATHY is a less commonly reported adverse event for CEFEPIME HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to encephalopathy, the following adverse reactions have been reported for CEFEPIME HYDROCHLORIDE:
The following drugs have also been linked to encephalopathy in FDA adverse event reports:
ENCEPHALOPATHY has been reported as an adverse event in 544 FDA reports for CEFEPIME HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ENCEPHALOPATHY accounts for approximately 1.9% of all adverse event reports for CEFEPIME HYDROCHLORIDE, making it a notable side effect.
If you experience encephalopathy while taking CEFEPIME HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.